The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 23, 2024
Filed:
Oct. 21, 2017
Cedars-sinai Medical Center, Los Angeles, CA (US);
Da Zen Theranostics, Inc., Beverly Hills, CA (US);
Liyuan Yin, Los Angeles, CA (US);
Yi Zhang, Los Angeles, CA (US);
Stefan Mrdenovic, Osijek, HR;
Gina Chia Yi Chu, Los Angeles, CA (US);
Ruoxiang Wang, Los Angeles, CA (US);
Qinghua Zhou, Chengdu, CN;
Jian Zhang, Ann Arbor, MI (US);
Leland W. K. Chung, Beverly Hills, CA (US);
Da Zen Theranostics, Inc., San Jose, CA (US);
Cedars-Sinai Medical Center, Los Angeles, CA (US);
Abstract
The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.